Lao Tzu said, "To see things in the seed, that is genius."

As investigative pathologists and pathobiologists, the members of ASIP have a special understanding of this ability. The genius of the discipline of pathology is that because of its focus on mechanisms of disease it operates at the intersection of basic and clinical biomedical sciences, which makes those involved in investigative pathology especially skilled at seeing the "seed" of clinical application in our research.

In reviewing the program for our 2003 Annual Meeting in April in conjunction with Experimental Biology 2003, that intersection is clearly displayed. Our program offers sessions that cover all the mission areas of academic medicine—research, education and clinical service, and explores the growing relationship between basic and clinical science and the fast-growing emphasis of biomedical investigation on translational research.

The ASIP sessions range from injury/repair to cancer to various aspects of cell expression, including multi-lineage stem cells. Our educational sessions will be useful to both new and experienced scientists, and EB2003 abstract sessions encompass virtually every type of disease mechanism and process.

The ASIP President’s Symposium - "The impact of host phenotype on disease expression and response to therapy" - is positioned to be at the translational intersection with respect to major disease processes: autoimmunity, infection, neoplasia, cardiovascular, and neurodegenerative.

I'm looking forward to an exciting meeting this year, as we move into a new phase for investigative pathology. For more information on the meeting, go to the ASIP Web site at www.asip.org.

I hope to see you in San Diego!

President's Symposium:
Monday, April 14, 2:00 p.m., Room 15A

Impact of Host Phenotype on Disease Expression and Response to Therapy
Chaired: Fred P. Sanfilippo
Co-Chaired: Abul K. Abbas

Genetics of autoimmunity—from gene to disease phenotype.
A.K. Abbas, Univ. of California, San Francisco

Enteroviral infections.
B.M. McManus, St. Paul's Hosp., Univ. of British Columbia

Prostate cancer as an example of the impact of host phenotype on human cancer initiation, progression, and response to therapy.

Alzheimer's disease: the convergence of genotype and molecular phenotype.
S.S. Sisodia, The Univ. of Chicago
From the Executive Officer’s Desk

Mark E. Sobel

ASIP on the move: March 1 marks my second anniversary as Executive Officer of ASIP. The job of Executive Officer is at times exhausting, but always stimulating, and I feel very fortunate to be able to serve ASIP in my current capacity. I have the advantage of working with an outstanding staff in the ASIP office as well as interested and talented volunteers from the membership who are helping to make ASIP the society for experimental and investigative pathologists. I am thrilled to report that in 2002, we had a record number of abstract submissions to our annual meeting and we received more applications for regular and trainee memberships than in the five previous years combined. See pages 12-16 for a list of new regular and trainee members who joined ASIP in 2002. Welcome to you all!!

New Benefits for ASIP Members: Last year, we added new membership benefits, and continued some other benefits that had been offered on a time-limited basis. For the first time, we offered discounts on publications from the AFIP (e.g. the so-called Tumor Fascicles) and Annual Reviews. We doubled the stipend for trainee travel awards to the annual meeting, more than doubled the number of recipients of awards, and added special awards for minorities. We re-vamped the ASIP website (www.asip.org) and are providing up-to-date information about upcoming meetings, news announcements, and job offerings. We also continued to offer our members a $750 rebate on color figures for manuscripts accepted to either The American Journal of Pathology (AJP) or The Journal of Molecular Diagnostics (JMD).

On-line submissions system for ASIP’s journals: Priscilla Markwood, ASIP Publication Manager, reports that the ASIP editorial office, which manages the review and production of AJP and JMD, recently completed the trial phase of an on-line submission system. The system, Rapid Review, is a product of Cadmus Professional Communications, parent company of Cadmus Journal Services that prints both journals. Priscilla will update the Society on Rapid Review’s impact on the authors at the Business Meeting during the annual meeting in San Diego on April 14. Most societies who have adopted this technology have realized significant improvements in average review time and in production schedules.

Search for a new Editor-in-Chief of AJP: Dr. Dorothy Bainton is the Chair of an ad hoc search committee to find a worthy successor to James Madara as AJP Editor-in-Chief. As this newsletter goes to press, we are close to naming the new Editor. An announcement will be made at the Business Meeting at the annual meeting in San Diego.

Annual Meeting in San Diego. I hope that you have made your travel plans for EB2003 in San Diego and that you have received the meeting announcement with the full ASIP Meeting Program. Included in the brochure (and also available on our website www.asip.org) are registration forms to register (for free) for special programs with space limitations:

- expanded program on graduate education in pathology (see page 9 for more details)
- Human Research Protection Programs 1a: How to Navigate Human Subject Protection Regulations, chaired by yours truly. (go to www.asip.org for more information)
- The ASIP Mentoring Luncheon: Dancing with Journals: A Guide to Submission and Review (see page 8 for more details)

Among the highlights at the meeting will be ASIP’s Business Meeting and Awards Reception, which will be held on Monday, April 14 (starting at 5:30 p.m.) at the Marriott Hotel, overlooking the San Diego Bay. Tara Zeitner, ASIP’s Director of Meetings and Membership Services, has ordered plenty of food and drink for all. Join us for the presentation of the Gold-Headed Cane to Dr. David Korn, the Rous-Whipple Award to Dr. Jan Reddy, the Chugai Award for Excellence in Mentoring and Scholarship to Dr. David Hajjar, and the Pfizer Outstanding Investigator Award to Dr. Charles Clevenger.

(Continued on page 4)
ASIP Honors David Korn with the Gold-Headed Cane Award

Dr. David Korn, Senior Vice President for Biomedical and Health Science Research at the Association of American Medical Colleges in Washington, D.C., is the recipient of the 2003 Gold-Headed Cane Award in recognition of long-term outstanding contributions to pathology. This award is the highest honor bestowed upon a member of this society.

The former President of ASIP (1987-1988—then the American Association of Pathologists) is a leader of investigative and academic pathology and was part of the early generation of pathologists committed to molecular biology of DNA replication. Among Dr. Korn’s many accomplishments, he was appointed by President Ronald Reagan as Chairman of the National Cancer Advisory Board from 1984 to 1991, he served on President Clinton’s Council of Advisors on Science and Technology, a panel on healthcare reform, and served on the Executive Board of the Federation of American Societies for Experimental Biology (FASEB).

“I have served with David on numerous councils, committees, and task forces on behalf of organized Pathology, including ASIP and the Association of Pathology Chairs. No one was as incisive or more supportive of the importance of research to pathology,” wrote the late Dr. Ramzi Cotran, former Chairman of both the Brigham and Women’s Hospital and Children’s Hospital Boston Departments of Pathology.

In June 1968, Dr. Korn accepted the positions of Professor and Chairman of the Department of Pathology at Stanford, as well as Chief of the Pathology Service at the Stanford University Hospital. He was able to transform a small pathology department into a department of national prominence by good recruitment and support for his staff. Under his mentorship, some of the earliest examples of translational research in molecular pathology were developed.

“At Stanford University, Dr. Korn converted a relatively small department into a powerhouse for both research and diagnostic pathology. His ability for recruiting, mentoring, and supporting faculty in both research and diagnostic anatomic pathology was phenomenal,” wrote Dr. Cotran.

Dr. Korn carried a number of administrative and consultative responsibilities outside of Stanford University, including serving as chairman of the Cell Biology Study Section and chairman of the Board of Scientific Counselors in the Division of Cancer Biology and Diagnosis at the National Cancer Institute. He also served on the Board of Trustees for the Worcester Foundation for Experimental Biology.

He was founder and Chairman of the Board of Directors of the California Transplant Donor Network, one of the largest organ procurement organizations. The Network helps patients in Northern and Central California and Northern Nevada receive organ and tissue transplants. In 1999, more than 200 donors provided life-sustaining organs for transplant.

Dr. Korn was also a founder of the Association for the Accreditation of Human Research Protection Programs, a nonprofit organization that offers accreditation to institutions engaged in research involving human participants. The association strives to raise the bar in human

(Continued on page 4)
research protection by helping institutions reach performance standards that surpass the threshold of state and federal requirements.

Recently, Dr. Korn has been active in representing the viewpoint of pathology and biomedical research to many important groups including members of the U.S. Senate and House of Representatives, the National Bioethics Advisory Commission, and the Board of Directors of FASEB.

“Dr. Korn has continued to make important contributions to pathology in his role as a senior statesman and spokesperson at the national level on issues including scientific integrity and scientific misconduct, conflict of interest, the protection of human subjects, and the challenges to academic health centers in the era of managed care,” said Dr. Richard Lynch, Hanson Professor of Immunology in the Department of Pathology, University of Iowa. “Dr. Korn has been particularly vocal and effective in articulating the position of pathologists and biomedical researchers with regard to the use of archival tissue samples in medical research.”

His leadership role has extended outside of pathology, including chairing the National Cancer Advisory Board for eight years service and serving on numerous committees of the National Institute of Medicine and National Academy of Sciences. He has also served as chairman of the special subcommittee to review the intramural research program of the National Cancer Institute.

Dr. Korn has been a member of the editorial boards of The American Journal of Pathology, The Journal of Biological Chemistry, and Human Pathology. He has written numerous scientific articles on biochemistry and molecular biology of DNA replication in human cells and in recent years also has written and spoken about issues of health and science policy.

Dr. Korn received his B.A. (summa cum laude) and M.D. (cum laude) from Harvard University and conducted his fellowship and residency in Pathology at Massachusetts General Hospital.

Dr. Korn is scheduled to receive the mahogany cane topped with a 14 karat gold head and an engraved band on April 14, 2003, during the ASIP’s annual meeting at Experimental Biology 2003 in San Diego.

ASIP’s Education Committee: ASIP has expanded its Education Committee, under the leadership of Dr. Linda McManus. See Linda’s report on page 9 for a summary of the various initiatives that the Committee is developing.

ASIP Companion Meeting at the USCAP Annual Meeting. ASIP will be presenting a symposium, “Early Cancer Detection: Integrating Morphology and Molecules” on Sunday, March 23 during the USCAP Annual Meeting, which will be held in Washington, DC. See the announcement on page 18 for more details.

Results of ASIP’s Elections: ASIP members voted in record numbers this year. I am very pleased to announce the following newly elected individuals to positions of leadership in the Society. They will take office on July 1, 2003.

• Vice President-elect: Stephen Galli
• Program Chair-elect: Martha Furie
• Councilors: Steven Kunkel and Mark Tykocinski
• Meritorious Awards Committee members: Joseph Madri and Michael Lamm
• Nominating Committee members: Avrum Gotlieb and George Michalopoulos

In the family: Congratulations to our members who have received special recognition in the last few months (see News and Notes on page 12). In addition, ASIP staff recently celebrated many wonderful events:

• Tara Zeitner began her term as President of the Gaithersburg/Germantown Jaycees.
• James Douglas and his wife Rachel had a baby girl, Morganne Juliette, on November 23.
• Terri Cash, ASIP’s Accounts Manager for its journals, married Steve Canterbury on December 14.
• Ruth Kelley (she’s the person behind the nice voice when you call ASIP’s main phone number) married Pat Sullivan on October 26.

I look forward to seeing you in San Diego!
Janardan K. Reddy Wins Rous-Whipple Award

Dr. Janardan K. Reddy, Chairman of Pathology at Northwestern University Medical School, is the recipient of the 2003 Rous-Whipple Award, presented annually by the American Society for Investigative Pathology (ASIP).

The Rous-Whipple Award is given to a pathologist with an illustrious career in research and continued productivity at the time of the award. With his ground-breaking research on peroxisomes, Dr. Reddy has distinguished himself as a researcher dedicated to the field of carcinogenesis.

Dr. Reddy began his career in India in 1961, as a Rotating House Office at the Osmania General Hospital in Hyderabad. Progressing from an instructor at Kakatiya Medical College to a postgraduate student at the All-India Institute of Medical Sciences, Dr. Reddy eventually moved to Kansas, where he stayed until 1976 before moving on to Northwestern.

Dr. Reddy’s pathology research is impressive when summed up by colleagues in the field. Dr. Peter Ward writes that Dr. Reddy’s “international stature in the field of peroxisomes and carcinogenesis, his many years of service to organizations such as the NIH and the Society of Toxicology, his senior status in the field of academic pathology, and his frequent invitation to participate in international symposia are hallmarks of a world-recognized academic pathologist.” Dr. Nelson Fausto notes “Dr. Reddy is one of the most distinguished scientists in academic pathology.” Adds Dr. Yashpal Kanwar, “He and his colleague, Dr. Sambasiva Rao, demonstrated that peroxisomal proliferation can be achieved by a variety of agents, including hypolipidemic drugs, and thus linked their biology to lipid metabolism, and that served as an impetus for the discovery of the peroxisomal β-oxidation system.” Dr. Rao, who worked closely with Dr. Reddy on these discoveries observed, “In the last 30 years no other single scientist contributed more to the understanding of peroxisome biology and peroxisome proliferator-induced hepatocarcinogenesis than Dr. Reddy. He has been universally recognized as a pioneer in this field . . . Dr. Reddy is a man of reason, unaffected by power and achievements, and always willing to help and guide anybody that approaches him. Dr. Reddy is a great teacher with a unique talent of simplifying complex problems.”

Dr. Reddy himself was pleased and honored to receive the Rous-Whipple Award. “The Rous-Whipple Award recognizes the work started approximately 35 years ago when I was a resident in pathology, beginning with a morphological phenomenon of increase in the number of peroxisomes (which were then called microbodies) in liver cells. Over the years, this work led to the identification of structurally diverse classes of chemicals - several lipid lowering drugs, certain phthalate ester plasticizers used in the manufacture of polyvinyl chloride plastics, herbicides and certain solvents - all of which exert similar effects - namely peroxisome proliferation. These are now called peroxisome proliferators, a designation we introduced in 1975.”

Dr. Reddy demonstrated that despite their structural diversity, various peroxisome proliferators induce the development of liver cancer, and act in a cell-specific manner by receptor-mediated mechanisms. Dr. Reddy identified a peroxisome proliferator-activated receptor (PPAR) subfamily that plays a pivotal role in lipid metabolism.

Dr. Reddy adds, “Thus the work has progressed from morphology to cell, biochemical and molecular biological, and genetic approaches to unravel the role of these receptors as sensors for endogenous and exogenous ligands. This has been, and continues to be, an exciting and fascinating journey. We still have a long way to go in terms of understanding the molecular complexity of cells and gene-specific and receptor-specific signal transduction. It is said that ‘a black belt is a white belt that never quits’ and research is the same way. Pursue with passion for there is more to go. I consider this award a tribute to the field and those who contributed to our understanding of this fascinating phenomenon.”

Dr. Reddy will receive a cash award and a plaque. The award will be presented on Monday, April 14, 2003, at the San Diego Marriott during ASIP’s Annual Meeting at Experimental Biology 2003. Dr. Reddy will also give a keynote lecture entitled, “Peroxisome Proliferators and PPARs: microbodies to biotic and xenobiotic sensing.”
Charles V. Clevenger Wins Pfizer Award

Dr. Charles V. Clevenger, Director of the DNA Flow Cytometry Facility at the University of Pennsylvania, is the winner of the 2003 Pfizer Outstanding Investigator Award, presented annually by the American Society for Investigative Pathology (ASIP), to recognize a young researcher under the age of 43 for meritorious research in experimental pathology.

Dr. Clevenger is being recognized for his breast cancer research. He has authored more than 40 peer-reviewed scientific articles and has served on numerous review committees and study sections. He is a former winner of the American Cancer Society Junior Faculty Research Award, as well as the Experimental Pathologist-In-Training Award, also given by the American Society for Investigative Pathology.

Nominating Dr. Clevenger, Dr. Leonard Jarrett noted, “recent evidence has demonstrated that prolactin serves as a chemoattractant for human breast carcinoma. Dr. Clevenger’s laboratory has been at the forefront of these efforts in characterizing the mechanism that regulate prolactin and its receptor expression in both normal and neoplastic tissues.”

Dr. Michael Prystowsky, a former mentor, remarked, “near the end of his training in my laboratory it was clear to the Department of Pathology at the University of Pennsylvania and to other departments around the country that Dr. Clevenger was a very promising physician scientist . . . [Dr. Clevenger’s] findings raise important new questions that may have significant diagnostic and therapeutic importance permitting us to predict tumor aggressiveness or devise therapeutic intervention based on . . . [prolactin] expression in human breast cancer.”

Dr. Clevenger felt that while winning the award was a “tremendous honor,” he found it humbling “to be included among a cadre of luminaries in the field of pathology.” He observed that his contribution to science was significant since his discoveries not only uncovered the fact that “prolactin significantly contributed to the development of breast cancer, but also revealed its mechanisms,” which is to say that his work resulted in “many new therapeutics for the treatment of breast cancer.”

Dr. Clevenger received his Honors B.S. in Medical Education and M.D. from Northwestern University. After receiving his Ph.D. at the Tumor Cell Biology Program from the same institution, he joined the Department of Pathology & Laboratory Medicine at the University of Pennsylvania, first as a resident, then as a Fellow in Cytopathology, and recently as a tenured member of the faculty.

Dr. Clevenger will receive a cash award and a bronze medallion. The award will be presented on Monday, April 14, 2003, at the San Diego Marriott during ASIP’s Annual Meeting at Experimental Biology 2003. Dr. Clevenger will give a keynote lecture on new paradigms of signal transduction in breast cancer.

For more information about all ASIP Awards
(and to download nomination and application forms)
Visit our web site—
www.asip.org/awds/awds.htm
The American Society for Investigative Pathology (ASIP) names Dr. David P. Hajjar, Dean of the Weill Graduate School of Medical Sciences at Cornell University, the winner of the 2003 Chugai Award for Excellence in Mentoring and Scholarship. Dr. Hajjar is recognized for his many significant contributions to the field of vascular biology, as well as acting as a mentor over 25 prominent scientists throughout the world.

Dr. Hajjar is the fourth scientist to receive the Chugai Award which was created in 2000 and is generously funded by Chugai Pharmaceutical Co., Ltd. The Award is presented to a member of the ASIP, with a distinguished career, who exhibits both excellence in mentoring and education and outstanding research achievements in experimental and investigative pathology.

Dr. Hajjar will receive a cash award and a plaque on April 14, 2003 during the ASIP’s annual meeting at Experimental Biology 2003 in San Diego. He will also present a keynote lecture on the regulation of cholesterol trafficking in the vessel wall, and will chair the Chugai Symposium for Young Investigators during the Annual Meeting.

Dr. Hajjar received his B.A. in Biochemistry at American International College in Springfield, Mass., in 1974, and his Ph.D. at the University of New Hampshire in 1978. In addition to serving as Dean for the Graduate School of Medical Sciences at Cornell University, Dr. Hajjar is the Director of the Center of Vascular Biology and the Frank H.T. Rhodes Distinguished Professor of Cardiovascular Biology and Genetics. He is on the editorial board of the American Heart Association’s Arteriosclerosis, Thrombosis, and Vascular Biology Journal.

Dr. Hajjar commented, “I am delighted to be the 2003 recipient of The Chugai Award for Excellence in Mentoring and Scholarship from the ASIP. Additionally, I am grateful to have had a steady stream of gifted trainees who have contributed intellectually to both the lab environment as well as to our understanding of the pathological basis of disease. I owe much of my professional success to this next generation of biomedical scientists who have trained in my laboratory, 90% of whom continue to conduct funded basic research in the academic arena. I hope that I may be remembered as much for those I have been fortunate enough to train as for the original contributions to my field. I believe The Chugai Award recognizes our collective accomplishments.”

Dr. Hajjar is the fourth scientist to receive the Chugai Award which was created in 2000 and is generously funded by Chugai Pharmaceutical Co., Ltd. The Award is presented to a member of the ASIP, with a distinguished career, who exhibits both excellence in mentoring and education and outstanding research achievements in experimental and investigative pathology.

Dr. Hajjar will receive a cash award and a plaque on April 14, 2003 during the ASIP’s annual meeting at Experimental Biology 2003 in San Diego. He will also present a keynote lecture on the regulation of cholesterol trafficking in the vessel wall, and will chair the Chugai Symposium for Young Investigators during the Annual Meeting.
Sneak Preview -
ASIP Career Development Workshop at EB '03 "Playing to Win - Elements of Success"
Sunday Morning, April 13, 2003,
Chaired by Jeanie McMillin and Nancy Thompson
Refreshments Provided

Why is it that some colleagues - arguably equally bright and well trained - seem to glide up the achievement and promotion ladder as if it were an escalator and for others it is an uphill climb on slippery rungs with a heavy backpack? Is career advancement all about working hard, good luck and whom you know? Well of course that's part of it, but the good news is that you can help make the system work for you even if you are not particularly lucky and don't know all the VIPs.

Knowledge and a plan are essential. The purpose of this session is to help you assemble a personalized career development toolbox to plan for your advancement, maximize your resources, save time and avoid burnout. Local and global resources are at your disposal.

Appearances count. Are you getting enough visibility and presenting yourself and your work in the most effective way? Women investigators in particular, may not be as visible and assertive in comparison to their male counterparts. Dr. Kate Loveland of University of Texas Medical School, Houston, will raise our consciousness of these issues and share some strategies for improvement.

You need grants and a productive lab for your career to advance. Time is precious. You can't afford not to know where to get really good information quickly. Turns out it is at your fingertips. Dr. Katie Cottingham of Science's Next Wave and GrantsNet will navigate you through some key databases for funding opportunities at all levels, and will tell you about a collection of career development information available online.

Now, back to your labs. Your lab needs to be running smoothly and to be optimally productive in order to generate the results needed for publications, grants and good science. Therefore, you need to recruit and train good people and pay close attention to the career development of these people. Does this become a vicious circle or a synergistic and satisfying experience? Dr. Kathy Barker, author of "At the Helm: A Laboratory Navigator", has researched the practices of many PI's and assembled some of their accumulated wisdom to bring us what might be called "lab management 101". Have you made any of the common mistakes? Learn how you can avoid some other pitfalls.

P.S. This workshop is open to everyone, at any career stage. Hope to see you there.

Coming Soon: A Women in Pathobiology Database is now under development by the CDWM Committee and is expected to be functional in time for the annual meeting. The primary goal of this web-based resource is to provide assistance in identifying women with particular expertise within the ASIP community for the purposes of selecting speaker and session chairs, candidates and reviewers for promotion/tenure committees, search committees, nominating committees, review panels, and general networking. Women in ASIP will soon receive an email asking for their participation and to provide some information about areas of research and clinical expertise. We also expect that this will be a useful mechanism to link those with specific expertise to those who desire mentors.
Education Committee

This committee has expanded to comprehensively address the educational activities of the organization; members include Abul Abbas (UCSF), Peter Anderson (U Alabama Birmingham), Robert Bowser (U Pittsburgh), Marion Cohen (UMDNJ), James Crawford (U Florida), John Kemp (U Iowa), Susan Koethe (MedCol Wis), Linda McManus (UTx Hlth Sci Ctr San Antonio), and Daniel Remick (U Mich). Ex officio members include Stanley Cohen (UMDNJ), Nancy Thompson (Brown U), William Coleman (UNC) and Mark Sobel (ASIP) as well as ASIP staff (Tara Zeitner, Director Meetings Membership Services, and Alta Wallington, Marketing Manager). Monthly conference calls are focused on the educational missions of the society. And, since almost all ASIP proceedings are “educational”, Education Committee activities are coordinated with those of other ASIP committees. To expedite Education Committee efforts, subcommittees have been established: (1) Trainee Issues (Bob Bowser); (2) Formal Courses (Susan Koethe); (3) Internet Resources (Pete Anderson); and (4) Outreach Programs (Marion Cohen). With an emphasis on “pathogenesis of disease,” recent Education Committee activities have included:

- development of state-of-the-art courses in various formats, e.g., traditional face-to-face meetings as well as web conferencing
- consideration of graduate education in coordination with that of other pathology organizations; Bob Bowser will represent ASIP in discussions of graduate education in pathology at meetings of the Association of Pathology Chairs
- response to the on-going NAS assessment and review of doctoral graduate programs at research universities in the US
- evaluation, enhancement, and expansion of ASIP trainee awards in order to recognize scientific accomplishments and to provide networking opportunities
- coordination of the Pathology Graduate Program Directors Meeting (at EB03)
- oversight of the ASIP-sponsored course, Pathobiology for Basic Scientists; Bill Coleman will assume Directorship after EB03
- development of an ASIP eLibrary to provide electronic resources in investigative pathology
- development of outreach programs for high school and undergraduate students

If you have ideas, want to offer an opinion, or volunteer for duty, please contact Linda McManus (mcmanus@uthscsa.edu), the ASIP office (tzeitner@asip.org), or any member of the committee.

Discussion of Pathology Graduate Education

Questions to consider:

How can you increase funding for your graduate program?
How can you attract qualified minority applicants?
What drives your curriculum?
How can pathology education exist within interdisciplinary graduate training programs?

The 3rd Annual Meeting of the Graduate Program Directors in Pathology will take place on Friday, April 11, 2003 at the ASIP Annual Meeting in San Diego. We will discuss four important topics related to graduate education:

1) The structure of Pathology Graduate Training programs
2) Curriculum in graduate training programs
3) Mentoring and minority recruitment
4) Funding opportunities for graduate students and training programs

While attendance of Graduate Program Directors is strongly encouraged, all those interested in graduate education and training opportunities should attend. This meeting will occur in the San Diego Marriott Hotel, Marriott Hall 5, from 11:00 AM – 5:00 PM on April 11, 2003. Lunch will be provided to all participants. Small group discussions will be focused on each topic to generate exciting educational opportunities. This will be a unique opportunity to network with colleagues from across the country and Canada, who are interested in graduate education. Registration is required; the form can be obtained from the ASIP website: www.asip.org/mtgs/EB03/graddir.htm

Suggestions or comments concerning the discussion topics can be emailed to Robert Bowser, Ph.D. (Program Organizer) at bowser@np.awing.upmc.edu or the ASIP office (tzeitner@asip.org). We look forward to your participation in this important program.
Milestones . . . in Investigative Pathology

Meisels, A. & Fortin, R.
Condylomatous Lesions of the Cervix and Vagina. I. Cytologic Pattern
Acta Cytologica 20:505-509, 1976 (A)

Meisels, A., Fortin, R. & Roy, M.
Condylomatous Lesions of the Cervix. II. Cytologic, Colposcopic and Histopathologic Study
Acta Cytologica 21:379-390, 1977 (B)

The two cited papers are landmark publications in the history of investigative pathology for several reasons, the most important of which is the profound and lasting impact they have had on women’s health. Today, we work in an era of biomedical research where there is a growing emphasis on “translational research.” This term usually means advancing clinical practice through the application of knowledge generated in the basic research laboratory. The studies of Meisels and colleagues (A,B) certainly had an immediate clinical impact, but their work is also an excellent example of translational research vectored in the reverse direction: observations made in the clinic stimulated basic research in the molecular genetics and biology of human papilloma viruses that advanced the field and continues to the present day. The investigations of Meisels employed an approach and a set of technologies, which by today’s standards would be considered rather simple. Their findings yielded fundamental insight into an important human cancer.

Compared to the numerous and often sophisticated tests that have been devised to detect the presence of a cancer, the simple technique for examining exfoliated cells in vaginal secretions described by the anatomist George Papanicolaou (1) has no peer when measured in terms of a public health impact. Before the Pap smear came into widespread use in the United States, cervical cancer was the leading cause of death from cancer in women, but it now ranks eighth. This dramatic fall in mortality rate reflects the early and effective treatment of asymptomatic patients whose vaginal cytology showed the presence of cancer cells, or cells indicative of a pre-malignant lesion. Although the mortality rate from cervical cancer is now relatively low, approximately one million cases of pre-cancerous conditions of the cervix are detected annually by Pap smears in the United States. In countries such as Viet Nam, where nationwide cytology screening does not occur, cervical cancer is the leading cause of death from cancer in women.

The investigations by Meisels and colleagues (A,B) were milestone contributions because they established that papilloma virus infection of the cells that line the uterine cervix was very common and that it was a high risk factor for the subsequent development of cervical cancer. At the time these studies were published, it was already known that a papilloma virus was the etiological agent of Condyloma acuminatum, a sexually transmitted disease that, because of the appearance of the lesions, is commonly referred to as venereal warts. These are benign squamous cell tumors that occur on the external genitals and the perineal skin in females and males. Instances of malignant transformation of these lesions had been reported in the literature, but were rare. Epidemiologic studies had established that the risk factors for developing venereal warts were the same as the risk factors for developing cervical cancer. These included sexual promiscuity and the initiation of sexual activity at an early age. A characteristic microscopic feature of venereal warts is the presence of a striking paranuclear halo in some of the squamous epithelial cells. Cytologists had occasionally observed cells with paranuclear halos in vaginal smears from women, who did not have a history of venereal warts, but these cells received little comment and their significance was unknown. The first published description of halo cells was in 1949 by J. Ernest Ayre, a pathologist at the Royal Victoria Hospital in Montreal, who considered them to be “precancerous cells” (2). The conspicuous halo present in these cells prompted Koss and Durfee in a 1956 paper (3) to designate them as koilocytes (koilos, the Greek word for hollow or cavity). Ayre (4) was the first to mention in the literature that halo cells might be a manifestation of a viral infection. Meisels’ investigations (A) established that the koilocytes present in vaginal secretions had cytological features in common with the halo cells present in venereal warts. In a very systematic study of otherwise normal women whose vaginal smears contained halo cells, Meisels and colleagues (B) detected focal alterations of the cervical surface which were rather inconspicuous and easily missed on routine clinical examination. Biopsies of these lesions revealed the presence of halo cells and other histological features indicating that they were flat or inverted condylomata. In contrast to the conspicuous papillary excrescences of
condyloma acuminatum of the external genitals and perineal skin, Meisels discovered that condyloma of the cervix were usually tiny, flat non-specific lesions that could easily be confused with other types of epithelial lesions. Once Meisels established the cytological criteria for condyloma (A), it soon became clear that most vaginal smears previously diagnosed as cervical dysplasia were actually cases of cervical condyloma.

In discussing their findings Meisels and colleagues (B) proposed that cervical condyloma might be an early step in the natural history of cervical neoplasia. The age of peak incidence of cervical condylomas in their study was 19 years, which is a significantly younger age than the peak incidence for carcinoma of the cervix. Since cervical condylomata eventually disappear, they proposed that the virus becomes latent, but that “later in life if host factors become favorable (lower immunity against the virus, repeated local trauma, infections and infestations of the cervix) the virus, probably now integrated in the host genome, activates the mechanisms of carcinogenesis.” The essence of their proposal remains valid today.

During the decades that followed publication of these milestone articles, the field of human papilloma virus (HPV) research has grown tremendously. More than 70 different types of HPV have been identified from clinical specimens and it is clear that a large number of subtypes and variants exist for each type of HPV. There is now an abundance of evidence that links HPV to cervical cancer and its precursor conditions. HPV DNA is detected in 85% of cervical cancers and 90% of cervical condylomata. Distinct HPV types (“high risk” types) are associated with cervical cancer. It is known that in condylomata, HPV exists in an episomal (non-integrated) form but in cervical cancer the HPV is integrated into the host genome. The site in the human DNA where HPV integration occurs is random, but the site where the viral DNA is interrupted during integration is selective and results in the over-expression of two viral proteins that block the action of two host-cell proteins that are key regulators of the cell cycle. Currently, clinical trials are testing the efficacy of vaccines containing peptides from high-risk types of HPV as an immunotherapeutic strategy to prevent HPV-associated genital cancers.

Collectively, these are impressive advances in a field that is rapidly approaching a detailed molecular understanding of an important human cancer. The studies of Meisels and colleagues provided a tremendous impetus to this field. The simple methodology developed by Papinicolaou set the stage. It is ironic that vaginal cytology – unquestionably the greatest success story in the field of human cancer, was initially met with such deep skepticism and strong resistance from within the discipline of pathology. Fortunately, the early practitioners of cytology persisted.

References:
1. Papanicolaou, G. N.
   New Cancer Diagnosis.
   Proceedings of the Third Race Betterment Conference, p. 528, 1928
   Diagnosis of Cancer by Vaginal Smears
   New York, 1943, The Commonwealth Fund
2. Ayre, J.E.
   The vaginal smear: “Precancer” cell studies using a modified technique.
   American Journal of Obstetrics and Gynecology 58:1205-1219, 1949
3. Koss, L.G. & Durfee, G.R.
   Unusual Patterns of Squamous Epithelium of the Uterine Cervix: Cytologic and Pathologic Study of Koilocytic Atyopia.
4. Ayre, J.E.
   Role of the Halo Cell in Cervical Carcinogenesis: A Virus Manifestation of Pre-malignancy
   Obstetrics and Gynecology 17:175-182, 1960

Update your on-line listing

To update your on-line listing in the FASEB Directory of Members

Go to www.faseb.org

Click on Member Directory at the left
Or

Go directly to http://12.17.12.70/fasebdir

Click Update Member Info at the top of your screen to make changes.

Please note: There is a time delay between submitting revisions and their actual appearance online.
News and Notes

ASIP Members Elected to the Institute of Medicine of the National Academies

Five members of the American Society for Investigative Pathology (ASIP) were elected to the Institute of Medicine of the National Academies. Candidates for this prestigious honor are selected for their contributions to biomedicine, social and behavioral sciences, law, administration, and economics; and those elected serve on a broad range of committees that study health policy issues. **Elected ASIP members include:**

**Abul K. Abbas, M.D.**, Professor and Chair, Department of Pathology, School of Medicine, University of California, San Francisco. Dr. Abbas is the current Vice-President of ASIP.

**Craig B. Thompson, M.D.**, Chair, Department of Cancer Biology, and Scientific Director, Abramson Family Cancer Research Institute, School of Medicine, University of Pennsylvania, Philadelphia.

**John Q. Trojanowski, M.D., Ph.D.**, Professor and Director of Medical Pathology, Department of Pathology and Laboratory medicine, School of Medicine, University of Pennsylvania, Philadelphia. Dr. Trojanowski has served on the ASIP Council.

**Irving L. Weissman, M.D.**, Karel and Avice Beekhuis Professor of Cancer Biology, Department of Pathology, Stanford School of Medicine, Stanford, California.

**Zena Werb, Ph.D.**, Professor of Anatomy, Department of Anatomy, School of Medicine, University of California, San Francisco.

ASIP Member Presented Prestigious Environmental Health Award

The Fundacion Mexicana para la Salud FUNSALUD (Mexican Foundation for Health), directed by Dr. Guillermo Soberón, former Secretary of Health, presented the prestigious "Matilde M de Santos" Award in Environmental Health to **American Society for Investigative Pathology (ASIP) member, Lilian Calderón-Garcidueñas, MD PhD.** Dr. Julio Frenk, Mexico's Secretary of Health, presented the Award in a ceremony that took place in Mexico City on November 5, 2002. Dr. Calderón's work includes research on the respiratory and systemic effects of air pollution on pediatric populations, and the effects of urban pollutants upon the brain. The award is given to a Mexican researcher that is involved in Environmental Health Issues and whose work is published in major journals.

Dr. Calderón is an active member of ASIP, and serves on the ASIP Long-Range Planning Committee.

**Welcome to the following NEW Regular Members (joined between January 1—December 31, 2002)**:

Sarki Abdulkadir, M.D., Ph.D.  
Univ of Alabama at Birmingham

Cristian L Achim, M.D., Ph.D.  
Univ of Pittsburgh Sch of Med

Geza Acs, M.D., Ph.D.  
Univ of Pennsylvania Med School

Yashpal Agrawal, M.D., Ph.D.  
Univ of Iowa

Khalid Amin, M.D.  
SRI International

Abbas Ardehali, M.D.  
UCLA

Jon C. Aster, M.D., Ph.D.  
Brigham & Women's Hosp

Alfred Ayala, Ph.D.  
Brown Univ/Rhode Island Hosp

Sheldon S. Ball, M.D., Ph.D.  
VA Greater Los Angeles HCS

Sanford H. Barsky, M.D.  
UCLA Sch of Med

Mary Beth Beasley, M.D.  
Providence Portland Med Ctr

David Berman, M.D., Ph.D.  
Johns Hopkins Medical Institutions

Jean Benard, Ph.D.  
Inst Gustave Roussy

Hanne Cathrine Bissgaard, Ph.D.  
Univ of Copenhagen

Stephen Blacklow, M.D., Ph.D.  
Brigham & Women's Hosp
<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robert Bowser, Ph.D.</td>
<td>Univ of Pittsburgh Sch of Med</td>
</tr>
<tr>
<td>Steven G. Brodie, Ph.D.</td>
<td>Univ of New Mexico Sch of Med HSC</td>
</tr>
<tr>
<td>Kyle E. Brown, M.D.</td>
<td>Univ of Iowa</td>
</tr>
<tr>
<td>Andre Buret, Ph.D.</td>
<td>Univ of Calgary</td>
</tr>
<tr>
<td>Steven L. Carroll, M.D., Ph.D.</td>
<td>Univ of Alabama at Birmingham</td>
</tr>
<tr>
<td>Diego H Castrillon, M.D., Ph.D.</td>
<td>Brigham &amp; Women's Hosp</td>
</tr>
<tr>
<td>Chin-Chao Chan, M.D.</td>
<td>National Eye Institute - NIH</td>
</tr>
<tr>
<td>John K. C. Chan</td>
<td>Queen Elizabeth Hosp</td>
</tr>
<tr>
<td>Lawrence Chan, M.D.</td>
<td>Univ of Illinois, Chicago</td>
</tr>
<tr>
<td>Wing C. Chan, M.D.</td>
<td>Univ of Nebraska Med Ctr</td>
</tr>
<tr>
<td>Kothapa N. Chetty, Ph.D., D.V.M.</td>
<td>Grambling State Univ</td>
</tr>
<tr>
<td>John C Cheville, M.D.</td>
<td>Mayo Clinic</td>
</tr>
<tr>
<td>Charleen T Chu, M.D., Ph.D.</td>
<td>Univ of Pittsburgh</td>
</tr>
<tr>
<td>Kevin P. Claffey Ph.D.</td>
<td>Univ of Connecticut Health Ctr</td>
</tr>
<tr>
<td>Brenda Lynn Coomber, Ph.D.</td>
<td>Univ of Guelph</td>
</tr>
<tr>
<td>Jose Costa, M.D.</td>
<td>Yale Univ Sch of Med</td>
</tr>
<tr>
<td>David W Courtman, Ph.D.</td>
<td>Univ of Toronto</td>
</tr>
<tr>
<td>Zoran Culig, M.D.</td>
<td>Univ of Innsbruck</td>
</tr>
<tr>
<td>Alan Daugherty, Ph.D., D.Sc.</td>
<td>Univ of Kentucky</td>
</tr>
<tr>
<td>Odile David, M.D.</td>
<td>Tulane Univ Sch of Med</td>
</tr>
<tr>
<td>Marie C. DeFrances, M.D., Ph.D.</td>
<td>Univ of Pittsburgh Med Ctr</td>
</tr>
<tr>
<td>Adel K. El-Naggar, M.D.</td>
<td>Univ of Texas, M.D. Anderson Can Ctr</td>
</tr>
<tr>
<td>Milton B Engel, D.D.S., M.S.</td>
<td>Univ of Illinois</td>
</tr>
<tr>
<td>Froilan Espinoza, M.D.</td>
<td></td>
</tr>
<tr>
<td>Jiang Lin Fan, M.D., Ph.D.</td>
<td>Univ of Tsukuba, Basic Med Sci</td>
</tr>
<tr>
<td>Soldano Ferrone, M.D., Ph.D.</td>
<td>Roswell Park Cancer Institute</td>
</tr>
<tr>
<td>Milan Fiala, M.D.</td>
<td>Univ of California, Los Angeles</td>
</tr>
<tr>
<td>Sydney Finkelstein, M.D.</td>
<td>Univ of Pittsburgh - Presbyterian Hosp</td>
</tr>
<tr>
<td>Nikolaos G. Frangogiannis, M.D.</td>
<td>Baylor College of Med</td>
</tr>
<tr>
<td>Salvatore Frasca Jr., VMD PhD DACVP</td>
<td>Univ of Connecticut</td>
</tr>
<tr>
<td>Henry F. Frierson Jr., M.D.</td>
<td>Univ of Virginia Med Ctr</td>
</tr>
<tr>
<td>Michael K. Fritsch, M.D., Ph.D.</td>
<td>Univ of Wisconsin</td>
</tr>
<tr>
<td>Andrea Frost, M.D.</td>
<td>Univ of Alabama at Birmingham</td>
</tr>
<tr>
<td>Koh Furuta, M.D., Ph.D.</td>
<td>National Can Ctr Hosp</td>
</tr>
<tr>
<td>Juan F Garcia, M.D.</td>
<td>Centro Natl de Invest Oncol</td>
</tr>
<tr>
<td>Andrea Herrera-Gayol, M.D., MSc, Ph.D.</td>
<td>Bioniche Therapeutics</td>
</tr>
<tr>
<td>Berhane Ghebrehiwet D.V.M. DSc</td>
<td>SUNY at Stony Brook Hlth Sci Ctr</td>
</tr>
<tr>
<td>John R Gordon, Ph.D.</td>
<td>Univ of Saskatchewan</td>
</tr>
<tr>
<td>Timothy C. Greiner, M.D.</td>
<td>Univ of Nebraska Med Ctr</td>
</tr>
<tr>
<td>Tara L. Haas, Ph.D.</td>
<td>York Univ</td>
</tr>
<tr>
<td>Patrick J. Haley, Ph.D.</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td>Zishan A. Haroon, M.D.</td>
<td>GeMune</td>
</tr>
<tr>
<td>Martin Hauer-Jensen, M.D., Ph.D.</td>
<td>Univ of Arkansas for Med Sci</td>
</tr>
<tr>
<td>Jonathan W. Heusel, M.D., Ph.D.</td>
<td>Univ of Iowa Col of Med</td>
</tr>
<tr>
<td>James M Holland, Ph.D., D.V.M.</td>
<td>Allergan Pharmaceutical</td>
</tr>
<tr>
<td>Jeffrey T. Holt, M.D.</td>
<td>Univ of Colorado Hlth Sci Ctr</td>
</tr>
<tr>
<td>Ralph Hruban, M.D.</td>
<td>Johns Hopkins Med Inst</td>
</tr>
<tr>
<td>Zdenek Hruban, M.D., Ph.D.</td>
<td>Univ of Chicago Med Ctr</td>
</tr>
<tr>
<td>Eric D. Hsi, M.D.</td>
<td>Cleveland Clinic Foundation</td>
</tr>
<tr>
<td>Tomomi Ibara, M.D., Ph.D.</td>
<td>Tochigi Inst of Clinical Pathology</td>
</tr>
<tr>
<td>Hiroshi Inagaki, M.D., Ph.D.</td>
<td>Nagoya City Univ Med Sch</td>
</tr>
<tr>
<td>Giorgio G.A. Inghirami, M.D.</td>
<td>New York Univ School of Med</td>
</tr>
<tr>
<td>Michael Ittmann, M.D., Ph.D.</td>
<td>Baylor College of Med</td>
</tr>
<tr>
<td>Olena Jacenko, Ph.D.</td>
<td>Univ of Pennsylvania Vet School</td>
</tr>
<tr>
<td>Richard C.K. Jordan, Ph.D. DDS</td>
<td>Univ of California San Francisco</td>
</tr>
<tr>
<td>Raghu Kalluri, Ph.D.</td>
<td>Beth Israel Deaconess Med Ctr</td>
</tr>
<tr>
<td>Kris Kalra, Ph.D.</td>
<td>BioGenex</td>
</tr>
<tr>
<td>Y. James Kang D.V.M. PhD</td>
<td>Univ of Louisville</td>
</tr>
<tr>
<td>Anne E. Kellogg, M.D.</td>
<td>East Carolina Univ Sch of Med</td>
</tr>
<tr>
<td>Darren Kelly, Ph.D.</td>
<td>St Vincent's Hosp</td>
</tr>
<tr>
<td>Abdel-Majid Khatib, Ph.D.</td>
<td>Ottawa Hlth Res Inst</td>
</tr>
<tr>
<td>Akos Koller, M.D., Ph.D.</td>
<td>New York Med Col</td>
</tr>
<tr>
<td>John J. Krolewski, M.D.-PhD</td>
<td>Univ of California, Irvine</td>
</tr>
<tr>
<td>Todd G. Kroll, M.D., Ph.D.</td>
<td>Emory Univ Medical Center</td>
</tr>
<tr>
<td>Masahiko Kuroda, M.D., Ph.D.</td>
<td>Tokyo Med Univ</td>
</tr>
<tr>
<td>Alex B Lentsch, Ph.D.</td>
<td>Univ of Cincinnati</td>
</tr>
<tr>
<td>W. Conrad Liles, M.D., Ph.D.</td>
<td>Univ of Washington</td>
</tr>
<tr>
<td>Volkhard Lindner, M.D., Ph.D.</td>
<td>MMC Research Institute</td>
</tr>
<tr>
<td>Michael P. Lisanti, M.D., Ph.D.</td>
<td>Albert Einstein Coll of Med</td>
</tr>
</tbody>
</table>
Youhua Liu, Ph.D.  
Univ of Pittsburgh

Guanyi Lu, M.D., Ph.D.  
Univ of Michigan

Anirban Maitra MBBS  
Johns Hopkins Med Inst

Rosemary Raouf Makar, M.D.  
Kuwait University

Alvin M. Malkinson, Ph.D.  
Univ of Colorado Hlth Sci Ctr

Eliezer Masliah, M.D.  
Univ California, San Diego Sch Med

L. Jeffrey Medeiros, M.D.  
Univ of Texas, MD Anderson Can Ctr

Michal Michal, M.D.  
Charles Univ

Gilbert W. Moeckel, M.D., Ph.D.  
Vanderbilt Univ

Sumathy Mohan, Ph.D.  
Univ of Texas HSC/San Antonio

Satdarshan P. S. Monga, M.D.  
Univ of Pittsburgh

Masatsugu Moriyama, M.D., Ph.D.  
Tottori Univ

Naofumi Mukaida, M.D., Ph.D.  
Kanazawa Univ Cancer Res Inst

Jerome B. Myers, M.D., Ph.D.  
Madigan Army Med Ctr

Kuniaki Nakanishi, M.D.  
National Defense Med Coll

James Nakashima Ph.D.  
Brown University

William G. Nelson, M.D., Ph.D.  
Johns Hopkins Univ

Irene Newsham, Ph.D.  
Henry Ford Hosp

Randal R. Nixon, M.D., Ph.D.  
Oregon Hlth Sci Univ

Asma Nusrat, M.D.  
Emory University

John Carl Oberholtzer, M.D., Ph.D.  
Univ of Pennsylvania Sch of Med

Juan Pablo Olano, M.D.  
Univ of Texas Med Branch

Tim D. Oury, M.D., Ph.D.  
Univ of Pittsburgh

Samuel Parks, M.D.  
Univ of Nevada Sch of Med

Jeff Parvin, M.D., Ph.D.  
Brigham & Women's Hosp

Ralf Paus, M.D.  
Univ of Hamburg

Elena Pegraro, M.D., Ph.D.  
Univ of Padova

Arie Perry, M.D.  
Washington Univ Sch Med

Miguel A. Piris, M.D., Ph.D.  
Centro Nacional de Invest Oncologicas

Luis Cristovao Porto, M.D., Ph.D.  
State Univ of Rio de Janeiro

Susan M. Pratiss, Ph.D. D.V.M.  
Yeshiva Univ

Neil Quigley, Ph.D.  
Molecular Pathology Lab Network

Elaine W. Raines, M.S.  
Univ of Washington/Harborview Med Ctr

Grant Ram,m, Ph.D.  
The Queensland Inst of Med Res

P. Srirama Rao, Ph.D.  
La Jolla Inst for Molecular Med

Jonathan S. Reichner, Ph.D.  
Rhode Island Hosp

Todd A. Reinhart ScD  
Univ of Pittsburgh

Jose Roberto Reyes Ramirez Sr., M.D.  
Univ Evangelica de El Salvador

Jorge A. Reyes-Esparza, M.D., Ph.D.  
Univ Autónoma del Estado de Morel

Arlin B. Rogers D.V.M. PhD  
MIT

Joan Rosello-Catafau, Ph.D.  
Inst de Invest Biomedicas de Barcelona

Mark A. Rubin, M.D.  
Brigham & Women's Hosp.

Fahumiya Samad, Ph.D.  
The Scripps Res Inst

Wade S. Samowitz, M.D.  
Univ of Utah Hlth Sci Ctr

Tara L. Sander, Ph.D.  
Children's Hosp

Trenton R. Schoeb D.V.M., PhD  
Univ of Alabama at Birmingham

Martin G. Schwacha, Ph.D.  
Univ of Alabama at Birmingham

Sanjeev Sethi M.D., Ph.D.  
Univ of Iowa Hosps & Clinics

Yuan Shao, M.D., Ph.D.  
Univ of Michigan Med Sch

Yong Shen, M.D., Ph.D.  
Sun Health Res Inst

Zhijun Shen, M.D.  
Medical Univ of South Carolina

Ie-Ming Shih, M.D., Ph.D.  
Johns Hopkins Univ

Atsuoyoshi Shimada, M.D.  
Aichi Inst for Developmental Res

Isao Shimokawa, M.D., Ph.D.  
Nagasaki Univ Grad Sch

Avtar K Singh, M.D.  
Medical Univ of South Carolina

Alan Solomon, M.D.  
Univ of Tennessee Grad School of Med

Jenny Southgate, Ph.D.  
Univ of York

Gregory L. Stahl, Ph.D.  
Brigham & Women's Hospital

James R. Stone, M.D., Ph.D.  
Brigham and Women's Hosp

Barry R. Stripp, Ph.D.  
Univ of Pittsburgh

Gloria H. Su, Ph.D.  
The Johns Hopkins Univ

Mark A. Suckow D.V.M.  
University of Notre Dame

Masao Sugamata, M.D., Ph.D. D.V.M.  
Tochigi Inst of Clinical Pathol

Haruhiko Sugimura, M.D., Ph.D.  
Hamamatsu Univ Sch Med

Xiuhua Sun, Ph.D.  
Univ of Louisville

Andrzej Tarnawski, M.D., Ph.D.  
Univ of California Irvine

Dennis J. Templeton, M.D., Ph.D.  
Univ of Virginia

Geoffrey M. Thiele, Ph.D.  
Univ of Nebraska Med Ctr

Robert W. Thompson, M.D.  
Washington Univ Sch of Med

*Please note: This list includes active (paid) ASIP Regular Members that joined between January 1, 2002 and December 31, 2002.
Welcome to the following NEW Trainee Members (joined between January 1—December 31, 2002):

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zita Arany</td>
<td>Ralf-Peter Czekay, Ph.D.</td>
<td>Narinder Gautam, Ph.D.</td>
</tr>
<tr>
<td>Univ of Maryland at Baltimore</td>
<td>The Scripps Res Inst</td>
<td>Weill Medical College of Cornell Univ.</td>
</tr>
<tr>
<td>Mihaela Avramut, M.D.</td>
<td>Darya Dabiri</td>
<td>Felicity N.E. Gavins</td>
</tr>
<tr>
<td>Univ. of Pittsburgh Sch. of Med.</td>
<td>iCapture Centre/ McDonald Res Labs</td>
<td>WHRI</td>
</tr>
<tr>
<td>Yu Bai, M.D., Ph.D.</td>
<td>Sanja Dacic, M.D., Ph.D.</td>
<td>Ryan M. Gill</td>
</tr>
<tr>
<td>UT Southwestern Med Ctr</td>
<td>Univ of Pittsburgh</td>
<td>Univ. of Kansas Med. Ctr</td>
</tr>
<tr>
<td>Lea Beaulieu</td>
<td>Rory R. Dalton, M.D.</td>
<td>Adrienne Goerges</td>
</tr>
<tr>
<td>Univ of North Carolina - Chapel Hill</td>
<td>Med College of Georgia</td>
<td>Boston Univ Sch of Med</td>
</tr>
<tr>
<td>Gourab Bhattacharjee, Ph.D.</td>
<td>Bidisha Dasgupta</td>
<td>German G. Gomez</td>
</tr>
<tr>
<td>The Scripps Research Institute</td>
<td>Weill Med Col of Cornell Univ</td>
<td>Univ of Colorado Hlth Sci Ctr</td>
</tr>
<tr>
<td>Abdel A.D. Bior, Ph.D.</td>
<td>Jessica N Del Bove, B.S.</td>
<td>Melva L. Gonzalez, M.D., Ph.D.</td>
</tr>
<tr>
<td>Temple Univ Sch of Med</td>
<td>UNC - Chapel Hill</td>
<td>Oklahoma University HSC</td>
</tr>
<tr>
<td>Jonathan Brody</td>
<td>Andrea del Pilar Lopez, M.D.</td>
<td>Pedram Hamrah, M.D.</td>
</tr>
<tr>
<td>The Johns Hopkins Univ.</td>
<td>Medical Univ of South Carolina</td>
<td>Harvard Med Sch</td>
</tr>
<tr>
<td>Patricia Burke, Ph.D.</td>
<td>Brendan C. Dickson, M.Sc.</td>
<td>Bing Han, M.D., Ph.D.</td>
</tr>
<tr>
<td>UC Davis</td>
<td>Univ of Toronto</td>
<td>Baylor Col of Med</td>
</tr>
<tr>
<td>Jennifer Bushman</td>
<td>Daniel Dion, M.D.</td>
<td>Xinbing Han, Ph.D.</td>
</tr>
<tr>
<td>UNC Chapel Hill</td>
<td>Centre Hospitalier Universitaire de Sher</td>
<td>Children's Memorial Hosp</td>
</tr>
<tr>
<td>Elisabeth Chalovich</td>
<td>Cagatay H Ersahin, M.D., Ph.D.</td>
<td>Lana Hanford</td>
</tr>
<tr>
<td>Univ. of Pittsburgh Sch. of Med.</td>
<td>Loyola Univ Med Ctr</td>
<td>Univ. of Pittsburgh</td>
</tr>
<tr>
<td>Jason Chan, Ph.D.</td>
<td>Mitra Esfandiarei</td>
<td>Valerie Hernandez-Hansen</td>
</tr>
<tr>
<td>Univ of Toronto</td>
<td>iCAPTURE Centre/McDonald Res Labs</td>
<td>Univ. of New Mexico School of Med.</td>
</tr>
<tr>
<td>Alex Chung Kyu Chin, M.Sc.</td>
<td>Wakesha Toinette Jeffcoat Evans</td>
<td>Charles Holst</td>
</tr>
<tr>
<td>Univ. of Calgary</td>
<td>Medical Univ. of South Carolina</td>
<td>Univ of California - San Francisco</td>
</tr>
<tr>
<td>Kanchan Chitaley, Ph.D.</td>
<td>Barbara M. Fenner</td>
<td>Paul J. Hoover</td>
</tr>
<tr>
<td>University of Washington</td>
<td>Univ. of Pittsburgh</td>
<td>National Institutes of Health</td>
</tr>
<tr>
<td>Joseph B. Clark, M.D.</td>
<td>Marxa Leao Figueired</td>
<td>Patrick C.H. Hsieh, M.D.</td>
</tr>
<tr>
<td>UNC - Chapel Hill</td>
<td>Univ of Wisconsin - Madison</td>
<td>University of Washington</td>
</tr>
<tr>
<td>David W Cohen</td>
<td>Mark S Forman, M.D., Ph.D.</td>
<td>Jennifer Jahn BS</td>
</tr>
<tr>
<td>Medical College of Ohio</td>
<td>University of Pennsylvania</td>
<td>UNC Chapel Hill</td>
</tr>
<tr>
<td>Amy L. Cole, Ph.D.</td>
<td>Wieslaw B. Furmaga, M.D.</td>
<td>Kyathanahalli Janardhan, BVSc, MVSc</td>
</tr>
<tr>
<td>UCLA</td>
<td>Hartford Hospital</td>
<td>Univ. of Saskatchewan</td>
</tr>
<tr>
<td>Adolfo Cotter, M.D.</td>
<td>Eva Gal-Gombos, M.D.</td>
<td>Sumag Jasani</td>
</tr>
<tr>
<td>SUNY Buffalo</td>
<td>MSMC</td>
<td>Magee Women's Hosp.</td>
</tr>
<tr>
<td>Robb E. Wilentz, M.D.</td>
<td>Ikuru Yazawa, M.D., Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Jon Williams, Ph.D.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tsung-Teh Wu, M.D., Ph.D.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Calendar of Events

The Sixth National HIPPA Summit
March 26-28, 2003; Washington, DC
www.hipaasummit.com/

Experimental Biology 2003
April 11-15, 2003; San Diego Convention Center, San Diego, CA
www.faseb.org

ASIP Annual Meeting
April 11-15, 2003; San Diego Convention Center, San Diego, CA
www.asip.org

Vascular Biology 2003
Annual Meeting of the North American Vascular Biology Organization
April 11-14, 2003; San Diego Convention Center, San Diego, CA
www.navbo.org

IBC’s 5th Annual Personalized Medicine
Practical Applications in Pharmaceutical Research Pipelines and in the Clinic
May 29-30, 2003 - Seaport Hotel, Boston, MA
www.lifesciencesinfo.com/2851

IBC’s 2nd Annual Molecular Diagnostics Towards Targeted Therapeutics
May 28-29, 2003 Seaport Hotel, Boston, MA
www.lifesciencesinfo.com/2851

The Pathophysiology of Diseases: from bench to bedside
37th Annual Meeting of the European Society for Clinical Investigation
Verona, Italy, 02-05 April 2003
www.esci.eu.com

Health Care Compliance Association's Compliance Institute 2003
April 27-30, 2003; New Orleans, LA
www.hcca-info.org

International Society for Biomedical and Environmental Repositories
May 4-7, 2003; Philadelphia, PA
www.isber.org

Molecular Biology in Clinical Oncology
June 27-July 4, 2003; Aspen, CO
www.aacr.org

Pathobiology of Cancer
July 13-20, 2003; Keystone, CO
www.aacr.org

30th Annual Meeting & Exposition of the Controlled Release Society
July 19-23, 2003; Glasgow, Scotland
www.controlledrelease.org/meetings/glasgow/index.htm

Association of Pathology Chairs Annual Meeting
July 23-26, 2003; Mount Tremblant, Quebec
www.apcprods.org

ASCO/AACR Workshop on Methods in Clinical Cancer Research
July 26-August 1, 2003; Vail, Colorado
www.vailworkshop.org

The XVth International Congress of Neuropathology
September 14-18, 2003; Turin, Italy
www.newtours.it/icnp2003

Association for Molecular Pathology Annual Meeting
November 20-23, 2003; Orlando, FL
www.ampweb.org

Developmental Vascular Biology Workshop
February 1-5, 2004; Asilomar Conference Center, Pacific Grove, CA
www.navbo.org

Critical Issues in Tumor Microcirculation, Angiogenesis and Metastasis:
Biological Significance and Clinical Relevance
June 2 -5, 2004, Harvard Medical School and Massachusetts General Hospital Boston, MA, USA
www.steele.mgh.harvard.edu

The XIIIth International Vascular Biology Meeting
June 1-5, 2004; Toronto, Ontario
www.ivbm2004.ca
Early Cancer Detection: Integrating Morphology and Molecules

Moderators:
Gene P. Siegal, University of Alabama School of Medicine, Birmingham, AL
Elizabeth R. Unger, Centers for Disease Control and Prevention, Atlanta, GA

- Morphologic and Molecular Methods for the Early Detection of Cancer: Competitors or Collaborators? - Jeffrey S. Ross, Albany Medical College, Albany, NY and Millennium Pharmaceuticals, Cambridge, MA
- NCI Director's Challenge and the Cancer Genome Anatomy Project: Interface with the Practicing Pathologist - Thomas J. Giordano, University of Michigan, Ann Arbor, MI
- Correlation Between Morphologic and Molecular Phenotypes of Renal Neoplasms. The Importance of the Surgical Pathologist in Recognizing New Hereditary Renal Syndromes - Maria J. Merino, National Cancer Institute, NIH, Bethesda, MD
- Biomarkers and Colonic Neoplasia - William E. Grizzle, University of Alabama at Birmingham, Birmingham, AL

Contributors:
President's Message: Fred P. Sanfilippo
sanfilippo.5@osu.edu

Executive Officer: Mark E. Sobel
mesobel@asip.org

Career Development, Women & Minorities:
Nancy Thompson – Nancy_Thompson@brown.edu

Education Committee:
Linda M. McManus - mcmanus@uthscsa.edu

Graduate Education Program: Robert Bowser
bowser@np.awing.upmc.edu

Meeting Information and Member News:
Tara A. Zeitner – tzeitner@asip.org

Editor/Public Affairs Committee/Milestones:
Richard G. Lynch – richard-lynch@uiowa.edu

Managing Editor: Bernadette M. Englert
benglert@asip.org

ASIP Telephone Directory
ASIP Society Office ...........(301) 634-7130
ASIP Fax .........................(301) 634-7990
Dr. Mark Sobel,
Executive Officer ............ (301) 634-7130
James Douglas,
Director of Finance ............(301) 634-7130
Tara Zeitner,
Meetings/Membership .......(301) 634-7950
Alta Wallington,
Marketing Manager ...........(301) 634-7948
Bernadette Englert,
Newsletter ......................(301) 634-7938
Ruth Sullivan,
Administrative Assistant .....(301) 634-7130

AJP/JMD Editorial Office .....(301) 634-7959
AJP/JMD Fax ....................(301) 634-7961
Priscilla Markwood,
Managing Editor ...............(301) 634-7959
Maria Giorla Eisemann,
Assistant Managing Editor ...(301) 634-7937
Assistant Editors:
Henry Carter .....................(301) 634-7933
Michael Dustin .................(301) 634-7936
Kristina Ogilvie,
Editorial Assistant ........... (301) 634-7944
Terri Canterbury,
Accounts Manager ............(301) 634-7934